CLINICAL_TRIALS
trial_result
· 2022-04-18
Clinical Trial Update: Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris [Phase 2]
Summary
Phase 2 clinical trial update for BTX 1503 in moderate to severe acne vulgaris has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Botanix Pharmaceuticals | Conditions: Acne Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2022-04-18